Cerity Partners LLC Has $904,000 Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Cerity Partners LLC grew its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 42.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,708 shares of the company's stock after acquiring an additional 12,110 shares during the period. Cerity Partners LLC owned about 0.06% of Kiniksa Pharmaceuticals International worth $904,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Peregrine Capital Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 26.7% during the first quarter. Peregrine Capital Management LLC now owns 309,190 shares of the company's stock worth $6,867,000 after purchasing an additional 65,147 shares in the last quarter. AMI Asset Management Corp grew its stake in shares of Kiniksa Pharmaceuticals International by 50.3% during the first quarter. AMI Asset Management Corp now owns 77,688 shares of the company's stock worth $1,725,000 after purchasing an additional 26,010 shares in the last quarter. Wealthquest Corp acquired a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth $42,000. Asset Management One Co. Ltd. acquired a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth $41,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth $301,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Insider Activity

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 15,211 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $28.75, for a total transaction of $437,316.25. Following the completion of the transaction, the chief accounting officer directly owned 32,546 shares of the company's stock, valued at $935,697.50. This trade represents a 31.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ross Moat sold 27,594 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total transaction of $800,777.88. Following the transaction, the insider directly owned 9,415 shares of the company's stock, valued at approximately $273,223.30. This represents a 74.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 429,504 shares of company stock valued at $12,027,601 in the last 90 days. Company insiders own 53.48% of the company's stock.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of analyst reports. Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research note on Sunday, July 6th. Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Finally, Jefferies Financial Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of "Buy" and a consensus target price of $39.67.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA traded down $0.57 on Friday, reaching $26.33. The company's stock had a trading volume of 623,373 shares, compared to its average volume of 963,104. The stock's 50-day moving average is $28.03 and its two-hundred day moving average is $23.70. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $30.69. The stock has a market capitalization of $1.92 billion, a P/E ratio of -105.32 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The firm's revenue for the quarter was up 72.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.25) earnings per share. Equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.